Sana reports Q1 net loss $49.4M, cash runway into 2026; new $119M ATM facility

Sana Biotechnology, Inc.

2025-Q1 EPS reported -$0.21

Net loss $49.4M ($0.21/share) vs $107.5M ($0.49/share) in Q1 2024; loss narrowed.
Cash $104.7M at Mar 31, 2025, down from $152.5M; non-GAAP cash burn $46.6M; runway into 2026.
Positive 12-week data for UP421 (HIP islet cells) in T1D: C-peptide production, immune evasion without immunosuppression.
Enrolling GLEAM (autoimmune) and VIVID (B-cell malignancies) trials; expect data in 2025.
New at-the-market (ATM) agreement with TD Cowen to sell up to $119M of common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.